Departments of Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Cancer Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
J Immunother Cancer. 2017 Oct 17;5(1):79. doi: 10.1186/s40425-017-0283-9.
Metastatic disease is the leading cause of death among cancer patients and involves a complex and inefficient process. Every step of the metastatic process can be rate limiting and is influenced by non-malignant host cells interacting with the tumor cell. Over a century ago, experiments first indicated a link between the immune system and metastasis. This phenomenon, called concomitant immunity, indicates that the primary tumor induces an immune response, which may not be sufficient to destroy the primary tumor, but prevents the growth of a secondary tumor or metastases. Since that time, many different immune cells have been shown to play a role in both inhibiting and promoting metastatic disease. Here we review classic and new observations, describing the links between the immune system and metastasis that inform the development of cancer therapies.
转移性疾病是癌症患者死亡的主要原因,涉及一个复杂而低效的过程。转移过程的每一步都可能受到限制,并受到与肿瘤细胞相互作用的非恶性宿主细胞的影响。一个多世纪前,实验首次表明免疫系统与转移之间存在联系。这种现象称为伴随免疫,表明原发性肿瘤诱导免疫反应,该反应可能不足以破坏原发性肿瘤,但可防止继发性肿瘤或转移的生长。从那时起,已经有许多不同的免疫细胞被证明在抑制和促进转移性疾病方面发挥作用。在这里,我们回顾了经典和新的观察结果,描述了免疫系统与转移之间的联系,这些联系为癌症治疗的发展提供了信息。